Literature DB >> 30233839

Neoadjuvant PD-1 blockade in lung cancer: we're not in Kansas anymore.

Brian Cohen1, M Blair Marshall1.   

Abstract

Entities:  

Year:  2018        PMID: 30233839      PMCID: PMC6129886          DOI: 10.21037/jtd.2018.07.98

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  11 in total

1.  Role of PD-1 and its ligand, B7-H1, in early fate decisions of CD8 T cells.

Authors:  Monica V Goldberg; Charles H Maris; Edward L Hipkiss; Andrew S Flies; Lijie Zhen; Rubin M Tuder; Joseph F Grosso; Timothy J Harris; Derese Getnet; Katharine A Whartenby; Dirk G Brockstedt; Thomas W Dubensky; Lieping Chen; Drew M Pardoll; Charles G Drake
Journal:  Blood       Date:  2007-03-28       Impact factor: 22.113

2.  Neoadjuvant PD-1 Blockade in Resectable Lung Cancer.

Authors:  Patrick M Forde; Jamie E Chaft; Kellie N Smith; Valsamo Anagnostou; Tricia R Cottrell; Matthew D Hellmann; Marianna Zahurak; Stephen C Yang; David R Jones; Stephen Broderick; Richard J Battafarano; Moises J Velez; Natasha Rekhtman; Zachary Olah; Jarushka Naidoo; Kristen A Marrone; Franco Verde; Haidan Guo; Jiajia Zhang; Justina X Caushi; Hok Yee Chan; John-William Sidhom; Robert B Scharpf; James White; Edward Gabrielson; Hao Wang; Gary L Rosner; Valerie Rusch; Jedd D Wolchok; Taha Merghoub; Janis M Taube; Victor E Velculescu; Suzanne L Topalian; Julie R Brahmer; Drew M Pardoll
Journal:  N Engl J Med       Date:  2018-04-16       Impact factor: 91.245

Review 3.  Mechanisms of immune evasion by tumors.

Authors:  Charles G Drake; Elizabeth Jaffee; Drew M Pardoll
Journal:  Adv Immunol       Date:  2006       Impact factor: 3.543

Review 4.  Nivolumab: a review in advanced squamous non-small cell lung cancer.

Authors:  Gillian M Keating
Journal:  Drugs       Date:  2015-11       Impact factor: 9.546

5.  Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer.

Authors:  Scott N Gettinger; Leora Horn; Leena Gandhi; David R Spigel; Scott J Antonia; Naiyer A Rizvi; John D Powderly; Rebecca S Heist; Richard D Carvajal; David M Jackman; Lecia V Sequist; David C Smith; Philip Leming; David P Carbone; Mary C Pinder-Schenck; Suzanne L Topalian; F Stephen Hodi; Jeffrey A Sosman; Mario Sznol; David F McDermott; Drew M Pardoll; Vindira Sankar; Christoph M Ahlers; Mark Salvati; Jon M Wigginton; Matthew D Hellmann; Georgia D Kollia; Ashok K Gupta; Julie R Brahmer
Journal:  J Clin Oncol       Date:  2015-04-20       Impact factor: 44.544

6.  Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates.

Authors:  Julie R Brahmer; Charles G Drake; Ira Wollner; John D Powderly; Joel Picus; William H Sharfman; Elizabeth Stankevich; Alice Pons; Theresa M Salay; Tracee L McMiller; Marta M Gilson; Changyu Wang; Mark Selby; Janis M Taube; Robert Anders; Lieping Chen; Alan J Korman; Drew M Pardoll; Israel Lowy; Suzanne L Topalian
Journal:  J Clin Oncol       Date:  2010-06-01       Impact factor: 44.544

7.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

Authors:  Suzanne L Topalian; F Stephen Hodi; Julie R Brahmer; Scott N Gettinger; David C Smith; David F McDermott; John D Powderly; Richard D Carvajal; Jeffrey A Sosman; Michael B Atkins; Philip D Leming; David R Spigel; Scott J Antonia; Leora Horn; Charles G Drake; Drew M Pardoll; Lieping Chen; William H Sharfman; Robert A Anders; Janis M Taube; Tracee L McMiller; Haiying Xu; Alan J Korman; Maria Jure-Kunkel; Shruti Agrawal; Daniel McDonald; Georgia D Kollia; Ashok Gupta; Jon M Wigginton; Mario Sznol
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245

8.  Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease.

Authors:  Jing Liu; Stephen J Blake; Michelle C R Yong; Heidi Harjunpää; Shin Foong Ngiow; Kazuyoshi Takeda; Arabella Young; Jake S O'Donnell; Stacey Allen; Mark J Smyth; Michele W L Teng
Journal:  Cancer Discov       Date:  2016-09-23       Impact factor: 39.397

9.  Expansion and Activation of CD103(+) Dendritic Cell Progenitors at the Tumor Site Enhances Tumor Responses to Therapeutic PD-L1 and BRAF Inhibition.

Authors:  Hélène Salmon; Juliana Idoyaga; Adeeb Rahman; Marylène Leboeuf; Romain Remark; Stefan Jordan; Maria Casanova-Acebes; Makhzuna Khudoynazarova; Judith Agudo; Navpreet Tung; Svetoslav Chakarov; Christina Rivera; Brandon Hogstad; Marcus Bosenberg; Daigo Hashimoto; Sacha Gnjatic; Nina Bhardwaj; Anna Karolina Palucka; Brian D Brown; Joshua Brody; Florent Ginhoux; Miriam Merad
Journal:  Immunity       Date:  2016-04-19       Impact factor: 31.745

Review 10.  Nivolumab for second-line treatment of metastatic squamous non-small-cell lung cancer.

Authors:  Amanda Rounds; Jill Kolesar
Journal:  Am J Health Syst Pharm       Date:  2015-11-01       Impact factor: 2.637

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.